Ligand validation:6ZOC

3YI: (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-8-formyl-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptam ethyl-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acetate

3YI is a Ligand Of Interest in 6ZOC designated by the Author

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
6ZOC_3YI_B_1107	27%	69%	0.253	0.904	0.75	0.44	2	1	0	0	100%	1
6ZOB_3YI_A_1208	50%	39%	0.182	0.932	0.96	1.47	2	6	0	0	100%	1
6ZO7_3YI_A_1209	40%	41%	0.196	0.908	0.92	1.44	2	7	0	0	100%	1
6ZOH_3YI_B_1107	35%	39%	0.236	0.926	0.96	1.48	2	7	0	0	100%	1
6BEF_3YI_A_601	4%	52%	0.374	0.759	0.92	0.92	2	3	0	0	100%	0.97

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.